samedan logo
 
 
 
spacer
home > ebr > winter 2001 > genomex - 22nd-24th october 2001, londo
PUBLICATIONS
European Biopharmaceutical Review

GenomeX - 22nd-24th October 2001, Londo

The keynote presentation at Terrapin Pharma's second annual GenomeX conference was given by Arthur Holden, Founder and CEO of First Genetic Trust and Chairman of the SNP Consortium. This is the name given to the collaborative group of industry, academia and the charity The Wellcome Trust which set out to create a high density, high quality single nucleotide polymorphism (SNP) map of the human genome to be made available to all parties at no cost. Mr Holden set out the initial objectives of the Consortium, familiar to most people involved in the life science sector, but took this several stages further by presenting what we know about the SNP map generated to date, and by explaining how this data is now being used. We now know, for example, that there are approximately 1.8 million single base differences (SNPs) per individual, evenly distributed across chromosomes and across coding and non-coding regions. There is also at least one common SNP per linkage disequilibriumfragment (that is, per chromosome segment conserved during recombination - anywhere from five to 50kb).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines

Ajdovšcina, Slovenia & Bangkok, Thailand, 02 November 2021: BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today announced the successful development of an optimized mRNA manufacturing process.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement